$VRDN

Tousignant Jennifer (Chief Legal Officer) sold 14,212 shares of Viridian Therapeutics, Inc.\DE (VRDN) at $24.50 ($0.35M total) across 2 trades on 2026-08-19.

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Lumvoa ™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S

Viridian Therapeutics (NASDAQ:VRDN) is discussed after Goldman Sachs raised its price target to $39 from $35 and kept a Buy rating, citing FDA approval-related views on Lumvoa for thyroid eye disease versus Tepezza, including efficacy on proptosis, safety, and easier dosing. Truist also raised its target to $38 from $35, projecting revenue by 2027.

Wells Fargo’s Mason Mendez said investors should stay invested despite volatility, citing a constructive equity view and a 2026 year-end S&P 500 target of 7,800 to 8,000, while noting high Q2 earnings expectations and leverage risks. The article highlights two Wells Fargo stock picks: Advanced Energy Industries (AEIS) and Viridian Therapeutics (VRDN), both with Strong Buy consensus ratings and double-digit upside potential.

Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).

Eurozone June economic confidence rose to 95.0 (+1.3), beating expectations of 94.3, and May M3 money supply increased 3.2% y/y vs 2.7% expected. Markets priced a ~7% chance of a 25 bp ECB hike on July 23. US stocks gained: KLAC +11%, PANW +9%, IRDM +25% on Rocket Lab’s ~$8B deal; several others rose or fell on upgrades, partnerships, and guidance.

Viridian Therapeutics said the U.S. FDA approved Lumvoa (veligrotug-vvze) for thyroid eye disease, its first commercial product. The company said the approval is based on Phase 3 THRIVE and THRIVE-2 trials, which met primary and secondary endpoints with improvements at week 15 in active and chronic TED. Lumvoa is a 12-week course. Viridian added that VRDN stock rose to $17.90 Friday and $19.81 after hours.

Seven Grand Managers LLC bought 100,000 shares of Viridian Therapeutics (NASDAQ:VRDN) in Q4, worth about $3.11M, raising its stake to ~0.10%, according to an SEC filing. Other investors increased positions, including Geode ($62.0M) and Fisher ($55.4M). Viridian reported Q earnings of -$0.90 EPS on $0.14M revenue (May 5).

Viridian Therapeutics (NASDAQ: VRDN) has priced upsized concurrent public offerings totaling $350 million. The financing includes $225 million in 1.75% convertible senior notes due 2032 and an equity offering of over 7.3 million shares at $17.00 per share. Net proceeds will be used to repay debt, fund market expansion studies for its thyroid eye disease franchise, advance early-stage research, and support general working capital.

Viridian Therapeutics has successfully raised approximately $359 million through a combination of convertible senior notes and an equity offering. The company issued $250 million in 1.75% Convertible Senior Notes due 2032 and raised roughly $117 million from an offering of 7.35 million common shares at $17.00 each. This capital will be used to repay debt, fund market expansion studies for its thyroid eye disease franchise, and advance its earlier-stage R&D pipeline.